Overhead view of cutout paper appliques representing stethoscope near syringe and capsules with pills on colorful background

HD news August: the latest in research and tech

This month, we received promising news on technological advances, findings from research teams, and the first in-human clinical trial of a new huntingtin-lowering treatment.  

Read on to discover what we learned in August, and what it means for our Huntington’s community in Australia.  

Phase 1 of new study begins in New Zealand

INSIGHTT is a new study testing SRP-1005, another huntingtin-lowering therapy that’s injected under the skin. The first in-human clinical trial is set to commence in the second quarter of 2026 in New Zealand. At this stage, researchers are only testing the safety of the treatment, and not whether it improves HD symptoms.  

Researchers are enrolling around 32 people, aged 21 to 70, who have undergone genetic testing for HD and are classified as HD-ISS Stage 2 or mild Stage 3. Although they aren’t currently recruiting in Australia, they do have plans to open further study centres later.  

We’ll keep you updated on news surrounding the INSIGHTT study as we learn it, including any news relating to Australia.  

Smartwatches could detect progression of HD  

Not only helpful for taking calls or checking your heart rate, smartwatches might also be used to detect progression of HD symptoms in individuals. Researchers in the UK and Switzerland developed a tool that measures movement of the wrists to estimate chorea severity in the upper limbs. According to the results, it does so more consistently than standard clinical assessments.  

As 90% of people living with Huntington’s experience chorea, the digital tool could help estimate the progression of this symptom, allowing people a better understanding of how their HD is advancing.

Person interacting with a smartwatch, showing a fitness application on the screen.

AI ‘intrabodies’ could assist in treating Huntington’s  

With help from artificial intelligence (AI) and an international team, researchers recently created small antibody fragments that they can produce inside human cells. Once there, the microscopic molecules may be able to target proteins that cause Huntington’s and other neurodegenerative diseases, including MND and Alzheimer’s.  

The research took place at the University of Essex and potentially unlocks a new way to study and treat neurodegenerative diseases from inside living cells. Although still an early advancement, it’s another hopeful pathway for treating Huntington’s in the future.  

A hopeful month  

August was full of exciting technology discoveries and news of upcoming trials to watch. As always, we’ll keep you up to date with any advancements.  

For more news on Huntington’s disease, read our News page and learn more about HD research in Australia here. 

Share this article

Similar Posts

View all news